Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daewoong Pharmaceutical Co., Ltd. (069620:KRX), powered by AI.
Daewoong Pharmaceutical Co., Ltd. is currently trading at ₩154,100. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daewoong Pharmaceutical Co., Ltd. on Alpha Lenz.
Daewoong Pharmaceutical Co., Ltd.'s P/E ratio is 71.7.
“Daewoong Pharmaceutical Co., Ltd. trades at a P/E of 71.7 (premium valuation) with modest ROE of 3.1%.”
Ask for details →Daewoong Pharmaceutical Co., Ltd. is a leading South Korean company in the pharmaceutical industry, focusing on the development, production, and distribution of medicinal drugs. With a strong emphasis on research and innovation, Daewoong is dedicated to creating advanced pharmaceuticals and medical devices that enhance healthcare solutions. The company's product portfolio includes prescription medicines aimed at treating chronic diseases, over-the-counter drugs, and biotechnology-driven therapies. It serves a wide array of sectors including hospital and retail pharmacies, contributing significantly to therapeutic advancements. Daewoong Pharmaceutical's commitment to innovation is evident through its substantial investments in R&D, fostering the development of novel drugs and treatments. The company leverages cutting-edge biotechnology and collaboration with global partners to ensure the delivery of high-quality healthcare solutions. Market presence across Asia and strategic expansion into new territories underscores its role as a pivotal player in the global pharmaceutical landscape. Harnessing technological advancements, Daewoong continues to enhance its product offerings and boost accessibility to healthcare, further cementing its market significance and reputation as a trusted healthcare provider.
“Daewoong Pharmaceutical Co., Ltd. trades at a P/E of 71.7 (premium valuation) with modest ROE of 3.1%.”
Ask for details →Daewoong Pharmaceutical Co., Ltd. (ticker: 069620) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,644 employees. Market cap is $1.8T.
The current price is ₩154,100 with a P/E ratio of 71.69x and P/B of 2.23x.
ROE is 3.10% and operating margin is 10.40%. Annual revenue is $1.4T.